Human Genome Epidemiology Literature Finder
|
Records 1 - 10 (of 10 Records) |
| Query Trace: Anemia and CALR[original query] |
|---|
| CALR mutation screening in pediatric primary myelofibrosis. Pediatric blood & cancer 2014 Dec 61 (12): 2256-62. An Wenbin, Wan Yang, Guo Ye, Chen Xiaojuan, Ren Yuanyuan, Zhang Jingliao, Chang Lixian, Wei Wei, Zhang Peihong, Zhu Xiaof |
| Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 2014 Aug 124 (7): 1062-9. Rumi Elisa, Pietra Daniela, Pascutto Cristiana, Guglielmelli Paola, Martínez-Trillos Alejandra, Casetti Ilaria, Colomer Dolors, Pieri Lisa, Pratcorona Marta, Rotunno Giada, Sant'Antonio Emanuela, Bellini Marta, Cavalloni Chiara, Mannarelli Carmela, Milanesi Chiara, Boveri Emanuela, Ferretti Virginia, Astori Cesare, Rosti Vittorio, Cervantes Francisco, Barosi Giovanni, Vannucchi Alessandro M, Cazzola Mario, |
| Frequency and molecular characteristics of calreticulin gene (CALR) mutations in patients with JAK2 -negative myeloproliferative neoplasms. Acta haematologica 2015 133 (2): 193-8. Wojtaszewska Marzena, Iwo?a Ma?gorzata, Lewandowski Krzyszt |
| Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status. European journal of haematology 2015 Jun . Mela Osorio María J, Ferrari Luciana, Goette Nora P, Gutierrez Marina I, Glembotsky Ana C, Maldonado Ana C, Lev Paola R, Alvarez Clarisa, Korin Laura, Marta Rosana F, Molinas Felisa C, Heller Paula |
| Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. Leukemia research 2017 Jun 60 18-23. Barosi Giovanni, Massa Margherita, Campanelli Rita, Fois Gabriela, Catarsi Paolo, Viarengo Gianluca, Villani Laura, Poletto Valentina, Bosoni Tiziana, Magrini Umberto, Gale Robert P, Rosti Vittor |
| Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. Oncotarget 2017 12 8 (60): 101735-101744. Rumi Elisa, Boveri Emanuela, Bellini Marta, Pietra Daniela, Ferretti Virginia V, Sant'Antonio Emanuela, Cavalloni Chiara, Casetti Ilaria C, Roncoroni Elisa, Ciboddo Michele, Benvenuti Pietro, Landini Benedetta, Fugazza Elena, Troletti Daniela, Astori Cesare, Cazzola Mario, |
| Momelotinib therapy for myelofibrosis: a 7-year follow-up. Blood cancer journal 2018 3 8 (3): 29. Tefferi Ayalew, Barraco Daniela, Lasho Terra L, Shah Sahrish, Begna Kebede H, Al-Kali Aref, Hogan William J, Litzow Mark R, Hanson Curtis A, Ketterling Rhett P, Gangat Naseema, Pardanani Anime |
| Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. Blood advances 2017 Sep 1 (20): 1729-1738. Spiegel Jay Y, McNamara Caroline, Kennedy James A, Panzarella Tony, Arruda Andrea, Stockley Tracy, Sukhai Mahadeo, Thomas Mariam, Bartoszko Justyna, Ho Jenny, Siddiq Nancy, Maze Dawn, Schimmer Aaron, Schuh Andre, Sibai Hassan, Yee Karen, Claudio Jamie, Devlin Rebecca, Minden Mark D, Kamel-Reid Suzanne, Gupta Vik |
| [Ruxolitinib combined with prednisone, thalidomide and danazol for treatment of myelofibrosis: a pilot study]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2019 2 40 (1): 24-28. Xu Z F, Qin T J, Zhang H L, Fang L W, Pan L J, Hu N B, Qu S Q, Li B, Xiao Z |
| Acute promyelocyte leukemia arose from CALR 1 mutated post essential thrombocythemia- myelofibrosis with splanchnic vein thrombosis: A case report. Leukemia research reports 2021 5 15 100243. Morsia E, Goteri G, Torre E, Garvey K B, Discepoli G, Tassoni A, Mancini S, Giantomassi F, Poloni A, Olivieri A, Rupoli |
- Page last reviewed:Feb 1, 2024
- Content source: